Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11851
CALL
Lexicon Pharmaceuticals
LXRX
$1.03B
| $49K | ﹤0.01% |
26,100
+6,100
| +31% | +$11.6K |
|
|
NCTY
11852
CALL
The9 Ltd
NCTY
$70M
| $49K | ﹤0.01% |
2,910
+1,150
| +65% | +$22.8K |
|
|
RGLS
11853
DELISTED
Regulus Therapeutics
RGLS
| $49K | ﹤0.01% |
+23,655
| New | +$57.4K |
|
11854
Savara
SVRA
$1.11B
| $49K | ﹤0.01% |
32,523
+19,952
| +159% | +$26.2K |
|
|
XNET
11855
Xunlei
XNET
$334M
| $49K | ﹤0.01% |
30,791
-35,683
| -54% | -$50.7K |
|
|
AIOT
11856
PowerFleet Inc
AIOT
$417M
| $49K | ﹤0.01% |
22,540
-1,551
| -6% | -$3.94K |
|
|
ARTEW
11857
DELISTED
Artemis Strategic Investment Corporation Warrant
ARTEW
| $49K | ﹤0.01% |
544,651
-1,330
| -0.2% | -$248 |
|
|
VLTA
11858
PUT
DELISTED
Volta Inc.
VLTA
| $49K | ﹤0.01% |
38,000
-67,000
| -64% | -$149K |
|
11859
CALL
Gerdau
GGB
$9.3B
| $48K | ﹤0.01% |
13,986
-24,696
| -64% | -$110K |
|
11860
CALL
Humacyte
HUMA
$168M
| $48K | ﹤0.01% |
15,000
-15,900
| -51% | -$88.4K |
|
11861
Marker Therapeutics
MRKR
$19M
| $48K | ﹤0.01% |
+14,432
| New | +$48K |
|
11862
PUT
PAVmed
PAVM
$37.2M
| $48K | ﹤0.01% |
114
-84
| -42% | -$40.6K |
|
11863
CALL
Pluri
PLUR
$17.3M
| $48K | ﹤0.01% |
4,925
-138
| -3% | -$1.7K |
|
|
GGRP
11864
CALL
Glimpse Group
GGRP
$19.6M
| $48K | ﹤0.01% |
+12,000
| New | +$52.8K |
|
|
TRONW
11865
DELISTED
Corner Growth Acquisition Corp. 2 Warrants
TRONW
| $48K | ﹤0.01% |
400,099
-231
| -0.1% | -$26 |
|
|
TTOO
11866
DELISTED
T2 Biosystems, Inc
TTOO
| $48K | ﹤0.01% |
59
-12
| -17% | -$17.8K |
|
|
ENERR
11867
DELISTED
Accretion Acquisition Corp Right
ENERR
| $48K | ﹤0.01% |
400,070
+70
| +0% | +$11 |
|
11868
CALL
StealthGas
GASS
$352M
| $47K | ﹤0.01% |
14,600
-35,800
| -71% | -$99.9K |
|
11869
LifeMD
LFMD
$166M
| $47K | ﹤0.01% |
23,400
-89,136
| -79% | -$221K |
|
11870
CALL
Mustang Bio
MBIO
$4.5M
| $47K | ﹤0.01% |
108
+18
| +20% | +$9.96K |
|
11871
Prenetics Global
PRE
$331M
| $47K | ﹤0.01% |
+783
| New | +$55.9K |
|
11872
CALL
RAVE Restaurant Group
RAVE
$43.2M
| $47K | ﹤0.01% |
43,500
+20,300
| +88% | +$20.1K |
|
11873
ZK International Group
ZKIN
$60.8M
| $47K | ﹤0.01% |
6,466
+3,890
| +151% | +$31.3K |
|
|
PCTI
11874
DELISTED
PCTEL, Inc. Common Stock
PCTI
| $47K | ﹤0.01% |
+11,533
| New | +$48.8K |
|
|
KBNT
11875
DELISTED
Kubient, Inc. Common Stock
KBNT
| $47K | ﹤0.01% |
+72,236
| New | +$75.6K |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.